{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.750","value":"7.13"},{"groupId":"OG001","spread":"0.479","value":"5.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.645","value":"-0.75"},{"groupId":"OG001","spread":"1.155","value":"0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CFB to 141 Weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Urine samples were collected to analyze urine pH levels. Baseline was defined as the latest pre-dose assessment within 21 days prior to first dose with a non-missing value, including those from unscheduled visits.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"MEAN","populationDescription":"All treated population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 141 weeks","title":"Part 1: Change From Baseline (CFB) in Urine Potential of Hydrogen (pH)","type":"PRIMARY","unitOfMeasure":"pH"}